Kiniksa Pharmaceuticals International Plc’s recently made public that its Officer Tessari Eben acquired Company’s shares for reported $0.49 million on Jun 16 ’25. In the deal valued at $28.28 per share,17,300 shares were bought.
Then, Quart Barry D sold 12,336 shares, generating $374,891 in total proceeds. Upon selling the shares at $30.39, the Director now owns 12,546 shares.
Before that, Quart Barry D sold 8,212 shares. Kiniksa Pharmaceuticals International Plc shares valued at $249,316 were divested by the Director at a price of $30.36 per share. As a result of the transaction, Quart Barry D now holds 12,546 shares, worth roughly $0.36 million.
Citigroup initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on March 13, 2025; the price target was $40. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Wells Fargo began covering KNSA with “an Overweight” recommendation on May 03, 2024. BofA Securities maintained its rating on June 29, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Monday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock jump 0.39% to $28.41. Over the last five days, the stock has lost -6.33%. Kiniksa Pharmaceuticals International Plc shares have risen nearly 43.63% since the year began. Nevertheless, the stocks have risen 50.08% over the past one year. While a 52-week high of $30.69 was reached on 06/11/25, a 52-week low of $17.38 was recorded on 01/13/25.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 27.81, which if violated will result in even more drops to 27.21. On the upside, there is a resistance level at 28.85. A further resistance level may holdings at 29.28.
The most recent change occurred on April 01, 2020 when BofA/Merrill began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
